Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) have been given a consensus rating of “Hold” by the twenty-four research firms that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $107.07.
ICPT has been the subject of several research analyst reports. Goldman Sachs cut Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. Deutsche Bank initiated coverage on Intercept Pharmaceuticals in a research report on Monday, February 12th. They set a “buy” rating and a $103.00 price objective for the company. Robert W. Baird restated an “outperform” rating and set a $253.00 price objective (down from $332.00) on shares of Intercept Pharmaceuticals in a research report on Thursday, January 25th. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, April 4th. Finally, Oppenheimer restated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Monday, January 29th.
In related news, major shareholder Francesco Micheli acquired 390,625 shares of the stock in a transaction dated Monday, April 9th. The stock was bought at an average cost of $64.00 per share, with a total value of $25,000,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Keith Michael Gottesdiener acquired 1,171 shares of the stock in a transaction dated Monday, April 9th. The shares were bought at an average cost of $64.00 per share, with a total value of $74,944.00. Following the completion of the purchase, the director now directly owns 5,001 shares in the company, valued at $320,064. The disclosure for this purchase can be found here. Insiders have bought a total of 399,608 shares of company stock valued at $25,574,912 over the last three months. Corporate insiders own 4.90% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in ICPT. Senvest Management LLC lifted its position in shares of Intercept Pharmaceuticals by 18.7% in the first quarter. Senvest Management LLC now owns 1,152,032 shares of the biopharmaceutical company’s stock worth $70,873,000 after purchasing an additional 181,106 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Intercept Pharmaceuticals by 101.5% in the fourth quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock worth $35,371,000 after acquiring an additional 304,999 shares during the last quarter. BB Biotech AG grew its stake in shares of Intercept Pharmaceuticals by 12.4% in the first quarter. BB Biotech AG now owns 545,719 shares of the biopharmaceutical company’s stock worth $33,573,000 after acquiring an additional 60,000 shares during the last quarter. Altrinsic Global Advisors LLC grew its stake in shares of Intercept Pharmaceuticals by 20.9% in the first quarter. Altrinsic Global Advisors LLC now owns 375,223 shares of the biopharmaceutical company’s stock worth $23,084,000 after acquiring an additional 64,923 shares during the last quarter. Finally, Elk Creek Partners LLC purchased a new stake in shares of Intercept Pharmaceuticals in the first quarter worth $21,437,000. 66.19% of the stock is owned by institutional investors.
NASDAQ ICPT traded down $0.21 during trading hours on Friday, reaching $69.78. The company’s stock had a trading volume of 1,179 shares, compared to its average volume of 471,848. The firm has a market cap of $2.07 billion, a PE ratio of -4.87 and a beta of -1.80. Intercept Pharmaceuticals has a 52 week low of $51.05 and a 52 week high of $135.59. The company has a debt-to-equity ratio of -6.88, a current ratio of 4.58 and a quick ratio of 4.58.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($3.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.41) by $0.19. The business had revenue of $35.96 million during the quarter, compared to analyst estimates of $38.44 million. Intercept Pharmaceuticals had a negative return on equity of 573.64% and a negative net margin of 241.33%. The company’s quarterly revenue was up 70.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.61) EPS. research analysts anticipate that Intercept Pharmaceuticals will post -11.66 earnings per share for the current fiscal year.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.